Abstract
The facultative intracellular pathogen and zoonotic agent Brucella sp. possesses two carbonic anhydrases (CAs, EC 4.2.1.1), termed bsCA I and bsCA II (in Brucella suis), belonging to the β-class of these metalloproteins. These zinc enzymes, present in many other pathogenic bacteria, have been considered recently as potential antibacterial targets. The catalytic activity of bsCA II is higher than that of bsCA I (for the conversion of CO2 to bicarbonate). Both enzymes were inhibited by the well-studied inhibitor acetazolamide, a sulfonamide drug. A library of 41 sulfonamides and one sulfamate, among which were 13 clinically tested drugs, was used for inhibition studies with bsCA I and II. These compounds were generally much more potent inhibitors of bsCA I (KIs of 17-75 nM) than of bsCA II (KIs of 84-923nM). However, certain glycosidic sulfonamide derivatives exhibited the same strong inhibitory activity on both bsCA I and bsCA II (KIs of 8.9-20 nM). Furthermore, at least one of these glycosylsulfonamides showed a significant inhibition of B. suis growth after 8-11 days of culture in minimal medium. In conclusion, as β-CAs of Brucella are susceptible to inhibition by a wide range of aromatic and heteroaromatic sulfonamides, they may represent novel targets for the development of clinically useful antibacterial agents.
Keywords: β-carbonic anhydrase, Brucella suis, inhibition, brucellosis, sulfonamide, zoonotic agent, carbonic anhydrases, metalloproteins, acetazolamide, sulfonamide drug, glycosidic sulfonamide, glycosylsulfonamides, cocco-bacilli, dendritic cells, Helicobacter pylori, Mycobacterium tuberculosis, bsCA I, sulfamate, methazolamide, ethoxzolamide, dichorophenamide, dorzolamide, brinzolamide, benzolamide, topiramate, zonisamide, sulpiride, indisulam, celecoxib, valdecoxib, glycosylsulfonamide
Current Pharmaceutical Design
Title: Brucella Carbonic Anhydrases: New Targets for Designing Anti-Infective Agents
Volume: 16 Issue: 29
Author(s): Jean-Yves Winum, Stephan Kohler and Claudiu T. Supuran
Affiliation:
Keywords: β-carbonic anhydrase, Brucella suis, inhibition, brucellosis, sulfonamide, zoonotic agent, carbonic anhydrases, metalloproteins, acetazolamide, sulfonamide drug, glycosidic sulfonamide, glycosylsulfonamides, cocco-bacilli, dendritic cells, Helicobacter pylori, Mycobacterium tuberculosis, bsCA I, sulfamate, methazolamide, ethoxzolamide, dichorophenamide, dorzolamide, brinzolamide, benzolamide, topiramate, zonisamide, sulpiride, indisulam, celecoxib, valdecoxib, glycosylsulfonamide
Abstract: The facultative intracellular pathogen and zoonotic agent Brucella sp. possesses two carbonic anhydrases (CAs, EC 4.2.1.1), termed bsCA I and bsCA II (in Brucella suis), belonging to the β-class of these metalloproteins. These zinc enzymes, present in many other pathogenic bacteria, have been considered recently as potential antibacterial targets. The catalytic activity of bsCA II is higher than that of bsCA I (for the conversion of CO2 to bicarbonate). Both enzymes were inhibited by the well-studied inhibitor acetazolamide, a sulfonamide drug. A library of 41 sulfonamides and one sulfamate, among which were 13 clinically tested drugs, was used for inhibition studies with bsCA I and II. These compounds were generally much more potent inhibitors of bsCA I (KIs of 17-75 nM) than of bsCA II (KIs of 84-923nM). However, certain glycosidic sulfonamide derivatives exhibited the same strong inhibitory activity on both bsCA I and bsCA II (KIs of 8.9-20 nM). Furthermore, at least one of these glycosylsulfonamides showed a significant inhibition of B. suis growth after 8-11 days of culture in minimal medium. In conclusion, as β-CAs of Brucella are susceptible to inhibition by a wide range of aromatic and heteroaromatic sulfonamides, they may represent novel targets for the development of clinically useful antibacterial agents.
Export Options
About this article
Cite this article as:
Winum Jean-Yves, Kohler Stephan and T. Supuran Claudiu, Brucella Carbonic Anhydrases: New Targets for Designing Anti-Infective Agents, Current Pharmaceutical Design 2010; 16 (29) . https://dx.doi.org/10.2174/138161210793429850
DOI https://dx.doi.org/10.2174/138161210793429850 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review
Current Pharmaceutical Biotechnology Naturally Occurring Peptides from Rana temporaria: Antimicrobial Properties and More
Current Topics in Medicinal Chemistry Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Nonbacterial Thrombotic Endocarditis (Marantic Endocarditis) in Cancer Patients
Cardiovascular & Hematological Disorders-Drug Targets Para-prosthetic Leaks Following Mitral Valve Replacement: Case Analysis on a 20-year Period
Current Cardiology Reviews The Use of Phages for the Removal of Infectious Biofilms
Current Pharmaceutical Biotechnology Appropriate Utilization of Restricted Antibiotics in a General Hospital of a Perfecture Area in Greece
Current Drug Safety Aminoglycoside Nephrotoxicity
Current Drug Targets - Infectious Disorders Synthesis, Structure and Antibacterial Evaluation of Some N-substituted 3-amino-5-hydroxy-4-phenyl-1H-pyrazole-1-carboxamides
Medicinal Chemistry Isolation of <i>Morganella Morganii</i> and <i>Providencia</i> Species from Clinical Samples in a Tertiary Care Hospital in North India
Infectious Disorders - Drug Targets Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Secondary Prevention of Ischemic Stroke
Current Drug Targets N-Containing Ag(I) and Hg(II) Complexes: A New Class of Antibiotics
Current Topics in Medicinal Chemistry TargetingQuorum Sensing and Competence Stimulation for Antimicrobial Chemotherapy
Current Drug Targets Ruptured Multiple Mycotic Aneurysms Following Infective Endocarditis: Effectiveness of Catheter-based Techniques Using N-butyl Cyanoacrylate in a Hemorrhage-induced Coagulopathy
Current Medical Imaging The Bovine Basic Pancreatic Trypsin Inhibitor (Kunitz Inhibitor): A Milestone Protein
Current Protein & Peptide Science Structure-Function Relationships in Anti-DNA and Anti-Phospholipid Antibodies and their Relevance to the Pathogenesis of Disease
Current Rheumatology Reviews Anti-Pathogenic Efficacy and Molecular Targets of a Polyherbal Wound- Care Formulation (Herboheal) Against Staphylococcus aureus
Infectious Disorders - Drug Targets Bivalirudin: Alternative Anticoagulation During Cardiopulmonary Bypass in Patients with Heparin-Induced Thrombocytopenia
Recent Patents on Cardiovascular Drug Discovery Long-term Outcomes of Mitral Valve Repair Versus Replacement for Degenerative Disease: A Systematic Review
Current Cardiology Reviews